Akari raises ~$5M in equity; exchanges $4M notes for warrants

On December 16, 2025, Akari Therapeutics, Plc (the “Company”) entered into a securities purchase agreement (the “RDO Purchase Agreement”) with certain institutional investors providing for the issuance and sale, in the Registered Direct Offering, of 10,043,774 American Depositary Shares (“ADSs”), each representing 2,000 ordinary shares, par value $0.000000005 per share (“Ordinary Shares”), of the Company.

In a concurrent Private Placement, pursuant to a securities purchase agreement dated as of December 16, 2025 (the “PIPE Purchase Agreement”, and, together with the RDO Purchase Agreement, the “Purchase Agreements”), the Company agreed to issue to certain directors and officers of the Company (i) unregistered pre-funded warrants (“Pre-Funded Warrants”, and, together with the Series G Warrants, the “Warrants”) to purchase an aggregate of 2,563,713 ADSs at an exercise price per ADS of $0.00001, and (ii) accompanying Series G Warrants to purchase an aggregate of 2,563,713 ADSs, at a combined purchase price of $0.4041 per Pre-Funded Warrant and Series G Warrant.

The Company also entered into a placement agency agreement (the “Placement Agent Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”), pursuant to which the Placement Agent agreed to serve as the exclusive placement agent for the Company in connection with the Offering.